Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
About this trial
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Eligibility criteria
Qualifiers
Localized WD-LPS and DD-LPS, and/or
WD-LPS or DD-LPS local relapse, and/or
WD-LPS or DD-LPS distant relapse and/or
Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- Blood sampling
Treatment groups
158 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov